Senti Bio Registers 25.6M Resale Shares — 82% of Outstanding — for Celadon and NSG Notes
SNTI sits 18% above its 52-week low of $0.29 on elevated volume (2.9× avg).
Summary
Senti Bio's resale registration for 25.6 million shares (82% of outstanding) is now effective, clearing the way for Celadon and NSG to convert $16 million of notes into a controlling equity stake.
Key Events · Financing and Capital Events · SNTI
-
Resale Registration Effective
The 424B3 prospectus makes effective the registration of 25,555,024 resale shares — 82.1% of the 31,144,754 shares outstanding as of June 30, 2026 — for Celadon (CPIF II-7 Limited) and NSG BioInnovation Fund.
-
Controlling Stake Conversion Path
If Celadon exchanges its $14.0 million of notes at the $0.6261 initial exchange price, it would beneficially own 60.0% of the company; if the remaining $24.0 million of notes are issued and exchanged, Celadon's ownership would reach 76.7%.
-
Exchange Price Far Above Market
The notes carry an initial exchange price of $0.6261 per share versus today's $0.342 price, meaning holders have no immediate economic incentive to convert — but the registration removes the procedural barrier to a controlling conversion.
-
Going Concern and Merger Vote
The prospectus reiterates the going-concern warning with cash only into Q4 2026, and the resale registration lands two weeks before the October 8 shareholder vote on the Celadon merger and 1-for-20 to 1-for-50 reverse stock split.
Analysis · SNTI · Life Sciences
The 424B3 makes effective the resale registration for 25,555,024 shares underlying $16.0 million of convertible notes held by Celadon and NSG. These shares represent 82.1% of the company's outstanding common stock, creating a massive overhang that could flood the public float. The notes carry an initial exchange price of $0.6261 per share — well above today's $0.342 price — meaning the holders have no economic incentive to exchange and sell at current levels. However, the registration removes the last barrier to a controlling-stake conversion: if Celadon exchanges its $14.0 million of notes, it would own 60.0% of the company, and up to 76.7% if the remaining $24.0 million of notes are issued and exchanged. This filing is the final step in a financing structure that hands control to Celadon ahead of the October 8 merger vote.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 985 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.29 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.